Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1516638 | 0.83 | ALDH1A1 (0.64) | KDM4EGLAMAPTPOLBPLAU | |
| SCHEMBL149589 | 0.83 | ALDH1A1 (0.44) | KDM4EMAPTPOLBALDH1A1MEN1 | |
| SCHEMBL12165513 | 0.82 | MAPT (0.46) | KDM4EMAPTPLAUALDH1A1TDP1 | |
| SCHEMBL29696047 | 0.82 | ALDH1A1 (0.46) | KDM4EGLAMAPTALDH1A1MEN1 | |
| SCHEMBL156978 | 0.82 | ALDH1A1 (0.46) | KDM4EGLAMAPTALDH1A1MEN1 | |
| SCHEMBL154689 | 0.81 | ALDH1A1 (0.45) | KDM4EGLAMAPTPOLBALDH1A1 | |
| SCHEMBL2472646 | 0.81 | KEAP1 (0.54) | KDM4EMAPTALDH1A1CLK1DYRK1A | |
| SCHEMBL10909 | 0.81 | ALDH1A1 (0.45) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL153277 | 0.81 | ALDH1A1 (0.71) | KDM4EMAPTPOLBALDH1A1MEN1 | |
| SCHEMBL26732 | 0.81 | ABL1 (0.49) | KDM4EGLAALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143662-A | Preparation method of 2- (2-amino-5-bromo-benzoyl) pyridine | 广西鲲宇药业有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-119143662-A | Preparation method of 2- (2-amino-5-bromo-benzoyl) pyridine | 广西鲲宇药业有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119143662-A | Preparation method of 2- (2-amino-5-bromo-benzoyl) pyridine | 广西鲲宇药业有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230257359-A1 | 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11458149-B1 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| CN-114502540-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | WYETH | 2003-03-06 | — | — | US | disclosed |
| US-6509334-B1 | This invention relates to compounds that antagonists of the progesterone receptor, their preparation and utility. Intracellular receptors (IR) form a class of structurally related gene regulators known as \"ligand dependent | AMERICAN HOME PRODUCTS CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-6498154-B1 | CONTRACEPTION; PROGESTATIONAL ACTIVE LEVONORGESTREL AND AN ANTIPROGESTIN COMPOUND | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-6444668-B1 | IN COMBINATION WITH A PROGESTIN, AN ESTROGEN, OR BOTH; ANTIPROGESTIN IS A 1,4-DIHYDRO-BENZO(D)(1.3)OXAZIN-2-ONE | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-6436929-B1 | 3,1-BENZOXAZINE-2-THIONES; CONTRACEPTION AND THE TREATMENT OF PROGESTERONE-RELATED MALADIES | WYETH | 2002-08-20 | — | — | US | disclosed |
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2002-07-18 | — | — | US | disclosed |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2002-04-25 | — | — | US | disclosed |
| US-6358948-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS AGAINST BREAST, PITUITARY, OVARIAN, ENDOMETRIUM, AND PROSTATE CANCER; BENIGN PROSTATIC HYPERPLASIA; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-1173426-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | GNRHR, PGR, PRLHR | KDM4E 2212/4885GLA 4667/4885MAPT 4878/4885 |
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | PGR, NR3C1, NR3C2 | KDM4E 2423/4885GLA 1697/4885MAPT 4855/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | KDM4E 972/4885GLA 1804/4885MAPT 507/4885 |
| US-20230257359-A1 | 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2A, MAT2B, MAT1A | KDM4E 811/4885GLA 3173/4885MAPT 1638/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | KDM4E 972/4885GLA 1804/4885MAPT 507/4885 |
| US-11458149-B1 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | KDM4E 972/4885GLA 1804/4885MAPT 507/4885 |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C1, NR5A1, CNR1 | KDM4E 2390/4885GLA 3263/4885MAPT 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.